Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Operations (2016 - 2025)

Regenxbio (RGNX) has 12 years of Cash from Operations data on record, last reported at 52290000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 65.35% year-over-year to 52290000.0; the TTM value through Dec 2025 reached 123963000.0, up 28.4%, while the annual FY2025 figure was 123963000.0, 28.4% up from the prior year.
  • Cash from Operations reached 52290000.0 in Q4 2025 per RGNX's latest filing, up from 55960000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 341497000.0 in Q4 2021 and bottomed at 80918000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 25205400.0, with a median of 46409500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: soared 765.25% in 2021, then crashed 111.53% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 341497000.0 in 2021, then plummeted by 111.53% to 39372000.0 in 2022, then decreased by 3.53% to 40760000.0 in 2023, then increased by 22.41% to 31624000.0 in 2024, then plummeted by 65.35% to 52290000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 52290000.0 in Q4 2025, 55960000.0 in Q3 2025, and 49342000.0 in Q2 2025.